Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BGM
Upturn stock ratingUpturn stock rating

Qilian International Holding Group Limited (BGM)

Upturn stock ratingUpturn stock rating
$11.97
Last Close (24-hour delay)
Profit since last BUY5.93%
upturn advisory
WEAK BUY
BUY since 40 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: BGM (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

0 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Year Target Price $0

Year Target Price $0

Analyst’s Price TargetsFor last 52 week
$0Target price
Low$3.33
Current$11.97
high$17.17

Analysis of Past Performance

Type Stock
Historic Profit -60.77%
Avg. Invested days 29
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.48B USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 1.46
52 Weeks Range 3.33 - 17.17
Updated Date 06/16/2025
52 Weeks Range 3.33 - 17.17
Updated Date 06/16/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.2

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -26.32%
Operating Margin (TTM) -5.41%

Management Effectiveness

Return on Assets (TTM) -3.84%
Return on Equity (TTM) -16.52%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2465318227
Price to Sales(TTM) 83.14
Enterprise Value 2465318227
Price to Sales(TTM) 83.14
Enterprise Value to Revenue 98.23
Enterprise Value to EBITDA 2801.9
Shares Outstanding 163960000
Shares Floating 2832616
Shares Outstanding 163960000
Shares Floating 2832616
Percent Insiders 7.29
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Qilian International Holding Group Limited

stock logo

Company Overview

overview logo History and Background

Qilian International Holding Group Limited was founded in 2011. It is a China-based pharmaceutical and chemical company focused on the development, manufacture, marketing, and distribution of traditional Chinese medicine products, chemical products, and medical appliances.

business area logo Core Business Areas

  • Pharmaceutical Products: Development, manufacturing, marketing, and distribution of traditional Chinese medicine products. Includes herbs, extracts, and finished medicines.
  • Chemical Products: Manufacturing and sales of chemical products. These products are used in various industrial applications, including pharmaceuticals and manufacturing processes.
  • Medical Appliances: Manufacturing and distribution of medical appliances and equipment.

leadership logo Leadership and Structure

The company's leadership team consists of executives with experience in the pharmaceutical and chemical industries. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and finance.

Top Products and Market Share

overview logo Key Offerings

  • Traditional Chinese Medicine (TCM) Products: Various TCM products, including herbal medicines and extracts. Market share data is difficult to ascertain precisely due to the fragmented nature of the TCM market in China. Competitors include other TCM manufacturers in China, such as China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
  • Chemical Products: Industrial chemicals used in pharmaceutical and other manufacturing processes. Market share is difficult to determine. Competitors: multiple Chinese chemical manufacturers.
  • Medical Appliances: A range of medical equipment, however, no information available for Market share is difficult to determine. Competitors: multiple Chinese medical appliance manufacturers.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry in China is experiencing rapid growth, driven by increasing healthcare spending and a growing aging population. The TCM market is also growing, driven by increasing acceptance of traditional medicine.

Positioning

Qilian International is a relatively small player in the Chinese pharmaceutical and chemical industries. Its competitive advantage lies in its focus on TCM products and its manufacturing capabilities.

Total Addressable Market (TAM)

The total addressable market for pharmaceuticals and chemicals in China is substantial, estimated to be hundreds of billions of dollars. Qilian International's positioning allows it to capture a small portion of this market.

Upturn SWOT Analysis

Strengths

  • Focus on traditional Chinese medicine
  • Manufacturing capabilities
  • Established distribution network within China

Weaknesses

  • Relatively small market share
  • Limited financial resources compared to larger competitors
  • Dependence on the Chinese market

Opportunities

  • Expanding into new geographic markets
  • Developing new TCM products
  • Acquiring smaller competitors

Threats

  • Increased competition from larger pharmaceutical companies
  • Changes in government regulations
  • Economic downturn in China

Competitors and Market Share

competitor logo Key Competitors

  • CRHKY
  • 000999.SZ
  • 600332.SS

Competitive Landscape

Qilian International faces intense competition from larger, more established pharmaceutical and chemical companies in China. Its smaller size and limited resources pose a disadvantage.

Growth Trajectory and Initiatives

Historical Growth: Insufficient data available to assess historical growth trends.

Future Projections: No reliable future projections are available due to limited information and potential delisting issues.

Recent Initiatives: It is difficult to ascertain recent strategic initiatives due to limited reporting.

Summary

Qilian International Holding Group Limited faces substantial challenges. The company's small market share and limited financial resources present significant hurdles in a competitive industry. However, its focus on traditional Chinese medicine provides a potential niche. Availability and reliability of financial data is a major concern, and the company requires strategic initiatives to improve its position and address competition.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (where available)
  • Industry reports
  • Financial news sources
  • Market research reports

Disclaimers:

The information provided is based on limited publicly available data and may not be entirely accurate or complete. This analysis is for informational purposes only and should not be considered investment advice. The situation surrounding Qilian International Holding Group Limited is dynamic and subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Qilian International Holding Group Limited

Exchange NASDAQ
Headquaters -
IPO Launch date 2024-08-12
CEO -
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 298
Full time employees 298

BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.